The National Center for Cancer Immune Therapy

​The aim of CCIT-DK is to improve our ability to bridge the gap between discovery and clinical implementation in the field of cancer immunotherapy.

​The National Center for Cancer Immune Therapy (CCIT-DK)

 CCIT-DK has a focus on development of immunological treatment of cancer, and has a research profile based on equally weighted experimental and clinical projects facilitating quick clinical implementation of new immunotherapies e.g. anti-CTLA4. It is the European leading centre for use of tumour infiltrating lymphocytes (TIL) for adoptive T-cell therapy (ACT) for metastatic melanoma. CCIT-DK provides the infrastructure of certified clinical grade laboratory for preparation of therapeutic cellular products and evaluations of immune responses.


The laboratory has extensive experience in production of both T-cells and DCs (including mRNA transfection) for clinical use. We also perform characterization of tumour antigens recognized by T cells, studies of T cell and dendritic cell (DC) biology and interactions, and biological monitoring of immune therapies of cancer, e.g. vaccination/DC trials and ACT.


Link to the homepage of CCIT - DK